Inhibition of experimental lung metastasis by aerosol delivery of PEI-p53 complexes

Molecular Therapy

Volumn 2, Issue 4, 2000, Pages 318-323

  Gautam, Ajay ^a   Densmore, Charles L ^a   Waldrep, J Clifford ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aerosol; B16 F10 melanoma; Gene therapy; Lung; Metastasis; p53; PEI

Indexed keywords

MURINAE;

LUCIFERASE; POLYETHYLENEIMINE; PROTEIN P53;

ANIMAL; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CELL DIVISION; DRUG EFFECT; EXPERIMENTAL MELANOMA; FEMALE; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; METHODOLOGY; MOUSE; PATHOLOGY; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADMINISTRATION, INHALATION; ANIMALS; CELL DIVISION; FEMALE; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAVENOUS; LUCIFERASES; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; POLYETHYLENEIMINE; SURVIVAL RATE; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034294818     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0138     Document Type: Article

References (30)

1. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878.
2. Lowe, S. W., et al. (1994). p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810.
3. Kafri, T., Morgan, D., Krahl, T., Sarvetnick, N., Sherman, L., and Verma, I. (1998). Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc. Natl. Acad. Sci. USA 95: 11377-11382.
4. DeMatteo, R. P., et al. (1999). Cellular immunity delimits adenoviral gene therapy strategies for the treatment of neoplastic diseases. Ann. Surg. Oncol. 6: 88-94.
5. Densmore, C. L., et al. (2000). Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol. Ther. 1: 180-188.
6. Gautam, A., Densmore, C. L., Xu, B., and Waldrep, J. C. (2000). Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery. Mol. Ther. 2: 63-70.
7. Missol, E., Sochanik, A., and Szala, S. (1995). Introduction of murine IL-4 gene into B16(F10) melanoma tumors by direct gene transfer with DNA-liposome complexes. Cancer Lett. 97: 189-193.
8. Missol-Kolka, E., Sochanik, A., and Szala, S. (1998). Combined therapy of B16(F10) murine melanoma using E. coli cytosine deaminase gene and murine interleukin-4 gene. Neoplasma 45: 305-311.
9. Qin, H., and Chatterjee, S. K. (1996). Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum. Gene Ther. 7: 1853-1860.
10. Kayaga, J., et al. (1999). Anti-tumor activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther. 6: 1475-1481.
11. Saito, M., Fan, D., and Lachman, L. B. (1995). Antitumor effect of liposomal IL 1 alpha and TNF alpha against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice. Clin. Exp. Metast. 13: 249-259.
12. Lesoon-Wood, L. A., Kim, W. H., Kleinman, H. K., Weintraub, B. D., and Mixson, A. J. (1995). Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum. Gene Ther. 6: 395-405.
13. Hsiao, M., et al. (1997). Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival. Biochem. Biophys. Res. Commun. 233: 359-364.
14. Xu, M., et al. (1997). Parenteral gene therapy with p53 inhibits human breast tu mors in vivo through a bystander mechanism without evidence of toxicity. Hum. Gene Ther. 8: 177-185.
15. Fidler, I. J., and Nicolson, G. L. (1978). Tumor cell and host properties affecting the implantation and survival of blood-borne metastatic variants of B16 melanoma. Isr. J. Med. Sci. 14: 38-50.
16. Densmore, C. L., Giddings, T. H., Waldrep, J. C., Kinsey, B. M., and Knight, V. (1999). Gene transfer by guanidinium-cholesterol:dioleoylphosphatidyl-ethanolamine liposome-DNA complexes in aerosol. J. Gene Med. 1: 251-264.
17. Nguyen, D. M., et al. (1997). Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex. Cancer Gene Ther. 4: 191-198.
18. Zou, Y., et al. (1998). Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J. Natl. Cancer Inst. 90: 1130-1137.
19. Swisher, S. G., et al. (1999). Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91: 763-771.
20. Orem, M. (1994). Relationship of p53 to the control of apoptotic cell death. Semin. Cancer Biol. 5: 221-227.
21. Kalechman, Y., Strassmann, G., Albeck, M., and Sredni, B. (1998). Up-regulation by ammonium trichloro(dioxoethylene-0,0′)tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: Implications for the antitumor effects of AS101. J. Immunol. 161: 3536-3542.
22. Li, S., et al. (1999). Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am. J. Physiol. 276: L796-L804.
23. Whitmore, M., Li, S., and Huang, L. (1999). LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6: 1867-1875.
24. Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
25. Kakolyris, S., et al. (1999). Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: Correlation with p53 and angiogenic factor expression. Cancer Res. 59: 5602-5607.
26. Fontanini, G., et al. (1999). Thrombospondins I and II messenger RNA expression in lung carcinoma: Relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin. Cancer Res. 5: 155-161.
27. Nishizaki, M., et al. (1999). Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect. Clin. Cancer Res. 5: 1015-1023.
28. Holmgren, L., Jackson, G., and Arbiser, J. (1998). p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene 17(7): 819-824.
29. Sheu, J. R., Fu, C. C., Tsai, M. L., and Chung, W. J. (1998). Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res. 18: 4435-4441.
30. Shalinsky, D. R., et al. (1999). Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. N.Y. Acad. Sci. 878: 236-270.